Positives

• In animal COPD models, treated subjects showed reduced goblet cell hyperplasia and lower TNF-alpha and IL-8, suggesting bronchial epithelium repair a long COVID patient with persistent cough may hope to mirror PubMed.
  
  
• A patient interested in epigenetic mechanisms can find reports describing Bronchogen as upregulating bronchial differentiation and surfactant gene expression rather than blocking a single receptor MDPI.
  
  

Negatives

• A patient evaluating efficacy will find that all published Bronchogen data come from Khavinson's St. Petersburg institute, with no independent Western replication and no randomized human trials MDPI.
  
  
• A patient looking for long COVID-specific evidence will find none; animal COPD work does not establish benefit for post-viral airway symptoms PubMed.
  
  

Hurdles & Side Effects

• A US patient cannot get Bronchogen from a regulated pharmacy because it is not approved for human use in any major jurisdiction outside Russia MDPI.
  
  
• A patient self-sourcing peptide vials must reconstitute with bacteriostatic water and inject or atomize without prescriber oversight, raising sterility and dosing risk PubMed.